Aragen Biologics introduced CHOMax, an integrated CHO cell‑line development and early GMP manufacturing platform designed to move antibody programs from DNA to IND‑enabling clinical supply in months. Aragen says CHOMax is refined across more than 200 CHO programs and supports parallelized CMC activities to compress timelines for standard IgG monoclonal antibodies. CHOMax bundles vector design, transfection, pool screening, single‑cell cloning, clone characterization and phase‑appropriate process development with analytics and GMP planning. Aragen positioned the platform to reduce typical time-to‑IND and support outsourced biologics manufacturing needs for biotech sponsors. The offering targets small and mid‑size biotechs seeking faster CMC cycles and a single-vendor path to clinical supply, reflecting increasing demand for end-to-end CDMO solutions that can accelerate early clinical programs.